RecruitingNCT05700149

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Sponsor

International Extranodal Lymphoma Study Group (IELSG)

Enrollment

300 participants

Start Date

Apr 11, 2024

Study Type

OBSERVATIONAL

Conditions

Nodal Marginal Zone Lymphoma

Summary

International retrospective observational cohort study aimed to describe a molecular classification for NMZL.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study analyzes tumor tissue samples from patients with nodal marginal zone lymphoma — a rare, slow-growing blood cancer that affects lymph nodes — using genetic and molecular profiling to better predict who will respond to treatment and who may relapse. **You may be eligible if...** - You are 18 or older - You were diagnosed with nodal marginal zone lymphoma based on a lymph node biopsy after January 2000 - Tumor tissue from your initial diagnosis (before any treatment) is available - Your medical records from diagnosis and follow-up are accessible **You may NOT be eligible if...** - Your lymphoma originated from an organ outside the lymph nodes that then spread to the nodes (this must have been ruled out by imaging or endoscopy) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(36)

University of Miami

Miami, Florida, United States

Weill Cornell Medical

New York, New York, United States

Hematology Center after Prof. Yeolyan

Yerevan, Armenia

University Hospital Centre Zagreb

Zagreb, Croatia

AO SS Antonio e Biagio e C. Arrigo

Alessandria, AL, Italy

Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.

Bari, BA, Italy

ASST Papa Giovanni XXIII

Bergamo, BG, Italy

ASST degli Spedali Civili di Brescia

Brescia, BS, Italy

AOU Policlinico Vittorio Emanuele, Presidio Ferrarotto

Catania, CT, Italy

Azienda Ospedaliero Universitaria di Ferrara

Cona, FE, Italy

Azienda Ospedaliera Universitaria Careggi

Florence, FI, Italy

Azienda Ospedaliera Papardo

Messina, ME, Italy

IRCCS Ospedale San Raffaele

Milan, MI, Italy

IEO Istituto Europeo di Oncologia

Milan, MI, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, MI, Italy

Azienda Sanitaria Locale di Pescara

Pescara, PE, Italy

Centro di Riferimento Oncologico

Aviano, PN, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, PV, Italy

AUSL IRCCS di Reggio Emilia, Arcispedale S. Maria Nuova

Reggio Emilia, RE, Italy

Fondazione PTV - Policlinico Tor Vergata

Rome, RM, Italy

Sapienza University - AOU Policlinico Umberto I

Rome, RM, Italy

Fondazione Policlinico Univeristario A. Gemelli, IRCCS, Università Cattolica S. Cuore

Rome, RM, Italy

ASST dei Sette Laghi - Ospedale di Circolo di Varese

Varese, VA, Italy

IRCCS - Azienda Ospedaliero-Universitaria di Bologna

Bologna, Italy

Azienda Ospedaliera Universitaria Federico II

Naples, Italy

AOU Maggiore della Carità

Novara, Italy

Portuguese Institute of Oncology

Lisbon, Portugal

Chonnam National University Hwasun Hospital

Hwasun-gun, South Korea

University Hospital Basel

Basel, Switzerland

Oncology Institute of Southern Switzerland and Institute of Oncology Research

Bellinzona, Switzerland

Hôpitaux Universitaires Genevois

Geneva, Switzerland

Kantonsspital St. Gallen

Sankt Gallen, Switzerland

University Hospital Zurich

Zurich, Switzerland

Leicester Royal Infirmary

Leicester, United Kingdom

Norfolk and Norwich University Hospital

Norwich, United Kingdom

Oxford University Hospitals

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05700149

Related Trials

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT042237651 location

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

NCT067969981 location